Chromothripsis-Mediated Small Cell Lung Carcinoma

Natasha Rekhtman, Sam E. Tischfield, Christopher A. Febres‐Aldana, Jake June-Koo Lee, Jason C. Chang, Benjamin Herzberg, Pier Selenica, Hyung Jun Woo, Chad Vanderbilt, Soo‐Ryum Yang, Fei Xu, Anita S. Bowman, Edaise M. da Silva, Anne Marie Noronha, Diana Mandelker, Miika Mehine, Semanti Mukherjee, Juan Blanco-Heredia, John J. Orgera, Gouri J. Nanjangud, Marina K. Baine, Rania G. Aly, Jennifer L. Sauter, William D. Travis, Omid Savari, André L. Moreira, Christina J. Falcon, Francis M. Bodd, Christina E. Wilson, Jacklynn V. Sienty, Parvathy Manoj, Harsha Sridhar, Lu Wang, Noura J. Choudhury, Michael Offin, Helena A. Yu, Àlvaro Quintanal-Villalonga, Michael F. Berger, Marc Ladanyi, Mark T.a. Donoghue, Jorge S. Reis‐Filho, Charles M. RudinCancer 2024 · DOI

TL;DR

This paper identifies a novel, aggressive subtype of small cell lung carcinoma (SCLC) in never-smokers, characterized by extensive chromosomal shattering (chromothripsis) and a distinct origin from pulmonary carcinoids. This discovery sheds light on a new pathway of SCLC development and suggests unique therapeutic vulnerabilities.

What Problem Does This Paper Address?

Small cell lung carcinoma (SCLC) is typically aggressive, strongly linked to smoking, and defined by the inactivation of two key tumor suppressor genes: RB1 and TP53. However, a small subset of SCLC patients, particularly never-smokers, present with tumors lacking these hallmark genetic alterations. The origins and underlying mechanisms of this "atypical" SCLC (aSCLC) have remained largely undefined, posing a challenge for diagnosis and treatment. This study aims to characterize this rare SCLC subtype, uncover its pathogenetic mechanisms, and explore its histogenetic origins.

Methods

The researchers employed a multi-omics approach, integrating:

  • Targeted Next-Generation Sequencing (tNGS): Used for initial screening of a large cohort of SCLC patients to identify those with RB1 and TP53 proficiency.
  • Whole-Genome Sequencing (WGS): Performed on a subset of aSCLC cases to provide a comprehensive view of genomic alterations, including structural variants (SVs) and copy number alterations (CNAs).
  • RNA Sequencing (RNA-seq): Used to analyze gene expression patterns and identify potential oncogenic fusions.
  • Immunohistochemistry (IHC): Employed to assess protein expression of key markers (e.g., pRb, p53, neuroendocrine markers, OTP, ASCL1, DLL3, SEZ6) and confirm genomic findings.
  • Fluorescence In Situ Hybridization (FISH): Utilized to validate gene amplifications, particularly extrachromosomal DNA (ecDNA) formation.
  • Bioinformatic Analysis: Custom algorithms and established tools were used for variant calling, CNA analysis, mutational signature analysis, and the detection of chromothripsis. A novel method was developed to detect chromothripsis in tNGS data.

Datasets

The study utilized data from:

  • A cohort of 600 SCLC patients who underwent tNGS at Memorial Sloan Kettering Cancer Center (MSKCC) as part of routine clinical care.
  • A newly characterized cohort of 20 aSCLC patients with RB1+/TP53+ status and low/no smoking history, who underwent extensive multi-omics profiling (WGS, RNA-seq, FISH, IHC).
  • Control datasets:
    • Smoking-associated SCLC (sSCLC) cohort (n=206) analyzed on the same platform.
  • Pulmonary carcinoid dataset (n=157).
  • Publicly available WGS datasets for lung adenocarcinoma (LUAD) and RB1-/TP53- SCLC.

Key Insights and Ideas

  • Chromothripsis as a Driver: The study reveals that extensive chromothripsis is a hallmark of this atypical SCLC subtype, driving oncogene amplification and tumor development. This is a significant departure from typical SCLC, which is characterized by point mutations and smaller-scale rearrangements.
  • Carcinoid Origin: A striking finding is the histogenetic link between aSCLC and pulmonary carcinoids, suggesting a novel pathway of SCLC pathogenesis originating from lower-grade neuroendocrine tumors. This challenges the long-held view of SCLC and carcinoids as entirely distinct entities.
  • Extrachromosomal DNA (ecDNA): The amplified oncogenes (CCND1, CCND2, CDK4, MDM2) are often found on ecDNA, also known as double-minutes. This mechanism allows for rapid and high-level gene amplification, contributing to tumor aggressiveness.
  • Dual Pathways for Never-Smokers: The paper proposes two distinct pathways for SCLC development in never-smokers: one linked to adenocarcinoma (via RB1/TP53 inactivation and APOBEC mutagenesis) and the other, identified here, linked to carcinoids (via chromothripsis and RB1/TP53 proficiency).
  • Therapeutic Vulnerabilities: The unique genomic alterations, particularly oncogene amplifications and high expression of DLL3 and SEZ6, suggest potential therapeutic targets and novel treatment strategies for this SCLC subtype.

Key Results

  • 20 aSCLC cases identified: Out of 600 SCLC patients screened, 20 (3%) exhibited RB1 and TP53 dual proficiency and a never/light smoker history, defining the aSCLC cohort.
  • Chromothripsis in 84% of aSCLC: Extensive chromothripsis was identified in 16 out of 19 non-MSI aSCLC cases analyzed by WGS and tNGS.
  • Recurrent oncogene amplifications: CCND1 (30%), CCND2/CDK4/+MDM2 (15%), and MYCL1 (10%) amplifications were recurrent and often associated with chromothripsis.
  • Histogenetic link to carcinoids: 55% of aSCLC cases showed features suggestive of a histogenetic relationship with pulmonary carcinoids (e.g., co-occurring carcinoid histology, OTP expression, characteristic genomic alterations).
  • Distinct clinicopathologic features: aSCLC patients were significantly younger, had a lower mean Ki67 proliferation index compared to other SCLC, and a history of absent/low pack-year smoking.
  • Intermediate Survival: aSCLC showed survival characteristics intermediate between smoking-related SCLC and atypical carcinoids.
  • Potential platinum insensitivity: Response rates to platinum-based chemotherapy were lower in aSCLC compared to historical rates for conventional SCLC.

Limitations and Future Work

  • Small cohort size: The study focused on a rare subtype, limiting the statistical power for detailed subgroup analyses and definitive conclusions on treatment efficacy.
  • Detection of chromothripsis in tNGS: While a method was developed, its sensitivity and specificity compared to WGS require further validation across larger datasets.
  • Functional validation: While strong associations were found, further experimental studies are needed to functionally validate the role of chromothripsis and ecDNA in aSCLC pathogenesis and to explore the proposed enhancer hijacking mechanism.
  • Therapeutic strategies: The study highlights potential therapeutic vulnerabilities, but clinical trials are needed to evaluate the efficacy of targeted agents in this specific SCLC subtype.
  • Distinguishing pathways: Further research is needed to fully delineate the distinct pathogenetic pathways of SCLC in never-smokers, particularly the interplay between genomic alterations, epigenetic reprogramming, and tumor microenvironment.

Summary updated

Abstract

Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we performed detailed clinicopathologic, genomic, and transcriptomic profiling of an atypical subset of SCLC that lacked RB1 and TP53 co-inactivation and arose in never/light smokers. We found that most cases were associated with chromothripsis-massive, localized chromosome shattering-recurrently involving chromosome 11 or 12 and resulting in extrachromosomal amplification of CCND1 or co-amplification of CCND2/CDK4/MDM2, respectively. Uniquely, these clinically aggressive tumors exhibited genomic and pathologic links to pulmonary carcinoids, suggesting a previously uncharacterized mode of SCLC pathogenesis via transformation from lower-grade neuroendocrine tumors or their progenitors. Conversely, SCLC in never-smokers harboring inactivated RB1 and TP53 exhibited hallmarks of adenocarcinoma-to-SCLC derivation, supporting two distinct pathways of plasticity-mediated pathogenesis of SCLC in never-smokers. Significance: Here, we provide the first detailed description of a unique SCLC subset lacking RB1/TP53 alterations and identify extensive chromothripsis and pathogenetic links to pulmonary carcinoids as its hallmark features. This work defines atypical SCLC as a novel entity among lung cancers, highlighting its exceptional histogenesis, clinicopathologic characteristics, and therapeutic vulnerabilities. See related commentary by Nadeem and Drapkin, p. 8.
BibTeX
@inproceedings{rekhtman2024chromothripsis,
  author = {Natasha Rekhtman and Sam E. Tischfield and Christopher A. Febres‐Aldana and Jake June-Koo Lee and Jason C. Chang and Benjamin Herzberg and Pier Selenica and Hyung Jun Woo and Chad Vanderbilt and Soo‐Ryum Yang and Fei Xu and Anita S. Bowman and Edaise M. da Silva and Anne Marie Noronha and Diana Mandelker and Miika Mehine and Semanti Mukherjee and Juan Blanco-Heredia and John J. Orgera and Gouri J. Nanjangud and Marina K. Baine and Rania G. Aly and Jennifer L. Sauter and William D. Travis and Omid Savari and André L. Moreira and Christina J. Falcon and Francis M. Bodd and Christina E. Wilson and Jacklynn V. Sienty and Parvathy Manoj and Harsha Sridhar and Lu Wang and Noura J. Choudhury and Michael Offin and Helena A. Yu and Àlvaro Quintanal-Villalonga and Michael F. Berger and Marc Ladanyi and Mark T.A. Donoghue and Jorge S. Reis‐Filho and Charles M. Rudin},
  title = {{Chromothripsis-Mediated Small Cell Lung Carcinoma}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1158/2159-8290.cd-24-0286},
}
Figure